Gilead Sciences, Inc. (GIS.F)
| Previous close | 62.06 |
| Open | 61.14 |
| Bid | 61.43 x 50000 |
| Ask | 61.45 x 50000 |
| Day's range | 61.14 - 61.55 |
| 52-week range | 57.58 - 80.08 |
| Volume | |
| Avg. volume | 563 |
| Market cap | 76.483B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 180.56 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.88 (4.65%) |
| Ex-dividend date | 14 June 2024 |
| 1y target est | N/A |
- Simply Wall St.
Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- GuruFocus.com
Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
Following this sale, the insider now owns 96,380 shares of Gilead Sciences Inc. Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's portfolio includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
- Insider Monkey
Should You Hold Gilead Sciences (GILD)?
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. In the first quarter, the Fund (Investor Shares) appreciated 10.17% outperforming the Russell 1000 Value Index’s 8.99%. Stock selection in the Information Technology and Communication Services sectors was the […]
